| Literature DB >> 34848888 |
Steven G Deeks1, Nancie Archin2, Paula Cannon3, Simon Collins4, R Brad Jones5, Marein A W P de Jong6, Olivier Lambotte7, Rosanne Lamplough8, Thumbi Ndung'u9,10,11, Jeremy Sugarman12, Caroline T Tiemessen13, Linos Vandekerckhove14, Sharon R Lewin15,16,17.
Abstract
Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong treatment is required and there is no cure. HIV can integrate in the host genome and persist for the life span of the infected cell. These latently infected cells are not recognized as foreign because they are largely transcriptionally silent, but contain replication-competent virus that drives resurgence of the infection once ART is stopped. With a combination of immune activators, neutralizing antibodies, and therapeutic vaccines, some nonhuman primate models have been cured, providing optimism for these approaches now being evaluated in human clinical trials. In vivo delivery of gene-editing tools to either target the virus, boost immunity or protect cells from infection, also holds promise for future HIV cure strategies. In this Review, we discuss advances related to HIV cure in the last 5 years, highlight remaining knowledge gaps and identify priority areas for research for the next 5 years.Entities:
Mesh:
Year: 2021 PMID: 34848888 DOI: 10.1038/s41591-021-01590-5
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440